Outpost Bio lands £2.6m pre-seed to predict drug-microbiome interactions via automated labs
This article covers Outpost Bio, a biotech startup, which has raised £2.6m in a pre-seed funding round co-led by Merantix Capital and Seedcamp. The funding will accelerate development of automated experimentation and machine-learning platforms to convert human microbiology data into predictive evidence that pharmaceutical, food and consumer startups can use to de-risk R&D, refine formulations and support regulatory dossiers.
Outpost Bio, a biotech startup, has raised £2.6 million in a pre-seed funding round co-led by Merantix Capital and Seedcamp to build computational models that make human microbiology data usable for product and drug development. The funding will accelerate its automated experimentation and modelling platforms to help pharmaceutical, food and consumer companies understand how microbial communities in and on the body change drug metabolism, nutrient processing and health outcomes.
Why it matters
Human-associated microbial communities are increasingly recognised as a factor in drug efficacy, formulation safety and nutrition, but linking complex microbiology data to actionable R&D decisions remains difficult. Outpost Bio aims to convert raw microbiome signals into predictive, experimental evidence that partners can use to de-risk clinical development, refine formulations and support regulatory dossiers. For companies working on consumer products or medicines, that translational gap can be decisive for whether a programme succeeds or stumbles in later-stage testing.
Inside the product
Outpost Bio combines automated wet-lab experimentation with machine learning in a closed feedback loop to generate and interpret human-derived functional data at scale. Its platform models the interaction layer of human biology — how microbes metabolise drugs or transform ingredients — rather than only cataloguing which species are present. That functional focus is intended to move teams from correlation to causal pathways, allowing simulation of microbial effects on candidate compounds and formulations before costly clinical work.
The company says the platform is aimed at pharmaceutical partners looking to identify microbiome-driven risks in clinical development, and at food and consumer companies seeking to test ingredient effects on microbial communities. The founding team includes expertise in microbiology, data engineering and machine learning, led by Dr Jenny Yang and Alex Merwin, and is supported by advisors from organisations including Ginkgo Bioworks, the Genome Sciences Centre and DARPA.
Who are the investors?
The round was co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC, Defined, and a group of strategic family offices and angel investors. The £2.6 million will be directed at scaling Outpost Bio’s experimental throughput and strengthening its modelling capability to produce human-derived datasets at greater volume and resolution.
In the announcement, Tom Wilson, Partner at Seedcamp, said:
This is a rare team that combines deep microbiology, machine learning, and company-building experience. Jenny, Alex, and the founding team have both the scientific rigor and operational insight required to build a new layer of biological infrastructure.
In the announcement, Adrian Locher, General Partner at Merantix Capital, said:
What took decades to build for earlier biological models can now be achieved in years. Faster wet-lab data generation, lower sequencing costs, and more powerful machine learning make this the right moment to build predictive models of the microbes that live within and on us.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
In the announcement, Jenny Yang, Co-founder & CEO at Outpost Bio, said:
We're building the most comprehensive dataset in human microbiology. Microbial communities can dramatically alter drugs and other interventions, yet this layer has been largely ignored because the data hasn't existed at scale. For the first time, we can move beyond correlations to reveal causal pathways.
Yang is an Oxford PhD and former Marie Curie Fellow with a background in clinical machine learning. Co-founder Alex Merwin was formerly Head of Growth for Health & Bio Startups at AWS. The founders position the company to bridge lab science and product development workflows by producing experimental evidence that partners can act on directly.
The bigger picture
Outpost Bio’s approach reflects a wider shift in biotech: cheaper sequencing, faster wet-lab automation and advances in machine learning are enabling companies to build predictive models of biological systems that were previously intractable. For pharmaceutical developers, the ability to anticipate microbiome-mediated drug transformations could reduce late-stage failures. For food and consumer companies, experimental data on ingredient–microbiome interactions can inform safer, more effective product design.
The deal also signals continued investor appetite for early-stage bioscience platforms in the UK and Europe. As regulatory scrutiny and consumer demand push companies to show robust evidence for safety and efficacy, startups that translate complex biology into usable datasets may find increasing commercial opportunities across health, food and consumer markets.
This funding round underlines how UK biotech founders are attracting capital for infrastructure-focused ventures that sit at the intersection of wet labs and machine learning, contributing to a maturing European ecosystem for computational biology.
They've invested in Outpost Bio
Get to know these biotech investors
Click here for a full list of 7,526+ startup investors in the UK